angiotensinogen

Angiotensinogen (1-14), human acetate 是血管紧张素原的片段，它是肾素-血管紧张素系统的被动底物。

Angiotensinogen (1-14), human TFA is a fragment of the renin substrate angiotensinogen, which is a precursor for all angiotensin peptides.

Angiotensinogen (1-13), human 是多肽分子，其序列是 DRVYIHPFHLVIH。

Angiotensinogen is a serum globulin formed by the liver that is cleaved by renin to form angiotensin I. Angiotensinogen is also called angiotensin precursor.

Acetyl Angiotensinogen (1-14), human 是多肽分子，其序列是 Ac-DRVYIHPFHLVIHN。

Angiotensinogen (1-14), porcine 是多肽分子，其序列是 DRVYIHPFHLLVYS。

Acetyl Angiotensinogen (1-14), porcine Acetate 是一种肽，序列为 AC-ASP-ARG-VAL-TYR-ILE-HIS-PRO-PHE-HIS-LEU-LEU-VAL-TYR-SER-OH。由血管紧张素原基因编码的蛋白质被称为前血管紧张素原或血管紧张素原前体。

Renin Substrate Tetradecapeptide, rat 是多肽分子，其序列是 DRVYIHPFHLLYYS。

Evazarsensodium 是一种血管紧张素原合成抑制剂，具抗高血压特性。

Renin FRET Substrate I is a specific compound that functions as a substrate for human renin. It is specifically designed to contain the exact cleavage site found in the N-terminal peptide of human angiotensinogen.

Angiotensin 1/2 (5-7) is a peptide with the sequence H2N-Ile-His-Pro-OH. Angiotensin is an oligopeptide and is a hormone and a powerful dipsogen. It is derived from the precursor molecule angiotensinogen, a serum globulin produced in the liver. It plays a

AG 84-10 is similar to Angiotensinogen 6-13. It is a peptidic substrate analog. It also has antihypertensive effects.

Tonlamarsen sodium is an angiotensinogen synthesis reducer with antihypertensive activity [1].

Renin inhibitory peptide is an analog of angiotensinogen.

H 77 is a new effective renin inhibitor. H 77 is angiotensinogen (6-13)-octapeptide in which the peptide bond -CO-NH- at the Leu(9)-Leu(11) linkage is replaced by a -CH2-NH- bond.

Angiotensin 1 2 (5-7) acetate 是一种具有 H2N-Ile-His-Pro-OH 序列的肽。血管紧张素是一种寡肽，是一种激素和一种强大的双肽原。它来源于前体分子血管紧张素原，一种在肝脏中产生的血清球蛋白。它在肾素-血管紧张素系统中起重要作用。

Angiotensin I II (1-6) TFA is a chemical compound comprising amino acids 1-6. It is derived from the Angiotensin I II peptide, which is formed by the cleavage of the precursor angiotensinogen by renin. The resulting Angiotensin I is then hydrolyzed by angiotensin-converting enzyme (ACE) to produce biologically active Angiotensin II. Angiotensin II has been extensively studied for its potential applications in the treatment of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy[1][2][3].